Sentences with phrase «from preclinical trials»

Not exact matches

«[A.I.] can help analyze large data sets from sources such as clinical trials, health records, genetic profiles, and preclinical studies; within this data, it can recognize patterns and trends and develop hypotheses at a much faster rate than researchers alone,» says Deloitte.

In those areas that we have mapped, it typically takes us a few hours to go from a mechanism - inspired idea for treating a disease to knowing the companies that might have relevant clinical and preclinical assets to license, the companies from whom a candidate could be commissioned, trial designs and endpoints, competing and complementary agents, current and future standard of care, market size, comparable pricing, financing strategy, and potential acquirers, all meant to enable a thoughtful first - pass assessment of whether an idea could be worth a much deeper assessment.

For example, Matt Krause, director of human resources at CV Therapeutics, says, «Our research programs include multiple, cutting - edge cardiovascular product candidates in various stages of clinical trials and preclinical programs, all of which rely heavily on the contributions from our many B.S. - and M.S. - level scientists.»

In his current role, he combines population research and functional genomics strategies to inform drug development from preclinical through phase 3 trials.

Formerly a research leader at CHOP, High pursued groundbreaking preclinical investigations in hemophilia B gene therapy and provided scientific expertise to previous gene therapy trials in hemophilia and other genetic disorders at CHOP before moving to Spark Therapeutics, which was spun off from CHOP in 2013.

Since eye and vision research can be conducted noninvasively, advancement of trials from the preclinical to the clinical phase could be relatively fast.

A Houston Methodist team led by Mauro Ferrari, PhD and Jenny Chang, MD has received funding from the U.S. Department of Defense to complete preclinical efficacy studies and a future clinical trial testing a breast cancer precision drug.

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

«Lithium, long used in mental health as a highly effective mood stabiliser, has been on the radar as a potential disease modifying treatment for Alzheimer's disease with positive evidence from preclinical studies and a number of small clinical trials.

The Wake Forest Institute of Regenerative Medicine (WFIRM) has a unique infrastructure that provides facilities and expertise for translational studies, from basic preclinical findings all the way through Phase 2 clinical trials.

Our researcher received a proof - of - concept grant from the Washington Life Sciences Discovery Fund, and worked with Washington State University and Malignext to conduct preclinical trials that produced results that will be helpful in future preclinical and clinical trials.

Cell therapy has been studied for multiple degenerative disorders and promising results from preclinical studies and clinical trials have been described for some.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

«So far, there has been a poor track record of moving things from preclinical discoveries into successful clinical trials,» says senior author Steve Finkbeiner, MD, PhD, a senior investigator at the Gladstone Institute of Neurological Disease and a professor of neurology and physiology at UCSF.

Your financial support will help us fund important research programs so that we can move our basic discoveries more rapidly from the proof - of - principle stage through translational research and preclinical testing that leads to human clinical trials.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

In his role as IDRI's Chief Medical Officer, Corey is developing and leading all clinical trial programs for IDRI from preclinical to Phase III, including oversight and management of data functions.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

Ward et al. highlight results from molecular and preclinical studies, discuss clinical trial results to date, describe ongoing investigations, and assess novel approaches for the enhancement of MSC based cardiac regeneration, such as genetic modification.

Recently, iBET became the coordinator of a research unit funded by FCT, iNOVA4Health, a translational medicine program organising the efforts of biomedical researchers involved in biological understanding of disease, lead compounds and biopharmaceuticals «pre-discovery», technological scientists involved in «preclinical development», and clinicians involved in «early clinical and first in man clinical trials» from institutions within NOVA University of Lisbon.

The Delaney Collaboratory to Cure HIV - 1 Infection by Combination Immunotherapy (BEAT - HIV Collaboratory) is a consortium of more than 30 top HIV researchers from leading academic research institutions working with government, nonprofit organizations, and industry partners to test combinations of several novel immunotherapies under new preclinical research and clinical trials.